Prognostic Value of Biomarkers in Patients with Honeycombing on HRCT
Author Information
Author(s): Hisata Shu, Kimura Yuichiro, Shibata Naoko, Ono Shuichi, Kobayashi Takao, Chiba Shigeki, Ohta Hiromitsu, Nukiwa Toshihiro, Ebina Masahito
Primary Institution: Tohoku University Graduate School of Medicine
Hypothesis
The study aims to evaluate the prognostic value of the divergence between SP-D and KL-6/MUC1 biomarkers in patients with idiopathic pulmonary fibrosis.
Conclusion
Patients with elevated SP-D but normal KL-6/MUC1 levels have a better prognosis compared to those with both biomarkers elevated.
Supporting Evidence
- Patients with only elevated SP-D had a longer survival time compared to those with both SP-D and KL-6 elevated.
- Immunohistochemical analysis showed distinct distribution patterns of SP-D and KL-6 in lung tissues.
- SP-D was significantly higher in asymptomatic patients compared to symptomatic patients.
Takeaway
Doctors found that some patients with lung issues had a special protein in their blood that could help predict how well they would do over time.
Methodology
The study involved a retrospective analysis of 28 patients with idiopathic pulmonary fibrosis, comparing serum levels of SP-D and KL-6/MUC1 and their clinical outcomes over 8–10 years.
Potential Biases
Potential bias due to the retrospective nature of the study and the inability to contact all patients for follow-up.
Limitations
The study had a small sample size and did not evaluate changes in lung function over time.
Participant Demographics
Patients included 11 asymptomatic and 17 symptomatic individuals, with ages ranging from 46 to 80 years.
Statistical Information
P-Value
0.0417
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website